In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae
Open accessAbstract
Background: Rezafungin is a novel echinocandin with excellent activity against common Candida species; however, limited data are available regarding rare Candida species. Methods: We determined the in vitro susceptibility of 689 clinical isolates of 5 common and 19 rare Candida species, as well as Saccharomyces cerevisiae. The activity of rezafungin was compared with that of anidulafungin, caspofungin, micafungin, amphotericin B and fluconazole, using CLSI broth microdilution methodology (Fourth Edition: M27). Results: Rezafungin MIC90 values were 0.06 mg/L for Candida albicans (n=125), Candida tropicalis (n=51), Candida dubliniensis (n=22), Candida inconspicua (n=41), Candida sojae (n=10), Candida lipolytica (n=10) and Candida pulcherrima (n=10), 0.12 mg/L for Candida glabrata (n=81), Candida krusei (n=53), Candida kefyr (n=52) and Candida fabianii (n=15), 0.25 mg/L for Candida lusitaniae (n=46) and Candida auris (n=19), 0.5 mg/L for Candida metapsilosis (n=15) and S. cerevisiae (n=21), 1 mg/L for Candida orthopsilosis (n=15) and Candida guilliermondii (n=27) and 2 mg/L for Candida parapsilosis sensu stricto (n=59). Caspofungin MIC90 values were 0.25–2 mg/L for all species, while micafungin and anidulafungin MIC90 values were similar to those of rezafungin. Fluconazole resistance was found in C. albicans (5.6%) and C. glabrata (4.9%); rezafungin was effective against these isolates as well. Amphotericin B MIC values did not exceed 2 mg/L. Conclusions: Rezafungin showed excellent in vitro activity against both WT and azole-resistant Candida species, as well as against S. cerevisiae. Rezafungin had similar activity to other echinocandins (excluding caspofungin) against common Candida species and, notably, against clinically relevant uncommon Candida species.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Rezafungin demonstrates potent in vitro activity against wild-type and azole-resistant Candida species.
“Like other echinocandins, RZF demonstrates potent in vitro activity against wild-type and azole-resistant Candida species [32, 33].”
From Investigational Agents for the Treatment of Resistant Yeasts and Molds (2021) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Pfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy358 · Cited by 825 · see citing works
Espinel-Ingroff, A., Arendrup, M. C., Pfaller, M. A., Bonfietti, L. X., Bustamante, B., Canton, E., Chryssanthou, E., Cuenca-Estrella, M., Dannaoui, E., Fothergill, A., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01519-13 · Cited by 216 · see citing works
Pfaller, M. A., Espinel-Ingroff, A., Canton, E., Castanheira, M., Cuenca-Estrella, M., Diekema, D. J., Fothergill, A., Fuller, J., Ghannoum, M., Jones, R. N., et al. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00248-12 · Cited by 174 · see citing works
Echinocandin Resistance, Susceptibility Testing and Prophylaxis: Implications for Patient Management
Perlin, D. S. (2014) · Drugs · doi:10.1007/s40265-014-0286-5 · Cited by 99 · see citing works
Sofjan, A. K., Mitchell, A. C., Shah, D. N., Nguyen, T. H., Sim, M., Trojcak, A., Beyda, N. D., & Garey, K. W. (2018) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2018.02.013 · Cited by 99 · see citing works
CD101: a novel long-acting echinocandin
Zhao, Y., Perez, W. B., Jiménez‐Ortigosa, C., Hough, G., Locke, J. B., Ong, V., Bartizal, K., & Perlin, D. S. (2016) · Cellular Microbiology · doi:10.1111/cmi.12640 · Cited by 81 · see citing works
Self-citationJames, K. D., Laudeman, C. P., Malkar, N. B., Krishnan, R., & Polowy, K. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01541-16 · Cited by 73 · see citing works
Pfaller, M. A., Messer, S. A., Rhomberg, P. R., & Castanheira, M. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.03.028 · Cited by 65 · see citing works
Pfaller, M. A., Castanheira, M., Diekema, D. J., Messer, S. A., & Jones, R. N. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.05047-11 · Cited by 62 · see citing works
Pfaller, M. A., Messer, S. A., Rhomberg, P. R., & Castanheira, M. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02045-16 · Cited by 53 · see citing works
Arendrup, M. C., Meletiadis, J., Zaragoza, Ó., Jørgensen, K. M., Marcos-Zambrano, L. J., Kanioura, L., Cuenca‐Estrella, M., Mouton, J. W., & Guinea, J. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.02.021 · Cited by 45 · see citing works
Majoros, L., Kardos, G., Belák, Á., Maráz, A., Asztalos, L., Csánky, E., Barta, Z., & Szabó, B. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.11.5250-5253.2003 · Cited by 32 · see citing works
Self-citationSzabó, Z., Tóth, B., Kovács, M., Kardos, G., Maráz, A., Rozgonyi, F., & Majoros, L. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.02350-07 · Cited by 22 · see citing works
Self-citationCyberlindnera fabianii in the neonatal and paediatric intensive care unit: case reports
Mlinarić-Missoni, E., Hatvani, L., Kocsubé́, S., et al. (2015) · JMM Case Reports · doi:10.1099/jmmcr.0.000032 · Cited by 17 · see citing works
Varga, I., Sóczó, G., Kardos, G., et al. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn403 · Cited by 15 · see citing works
Self-citationFothergill, A. W., McCarthy, D. I., Bataineh, M. T. A., Sanders, C. J., McElmeel, M., & Wiederhold, N. P. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.02659-15 · Cited by 14 · see citing works
Flagged first, then by citations
Research works printed but not linked: 3
- [10]Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts—Fourth Edition: M27 CLSI, Wayne, PA, USA, 2017.
- [11]Clinical and Laboratory Standards Institute. Performance Standards for Antifungal Susceptibility Testing of Yeasts—First Edition: M60 CLSI, Wayne, PA, USA, 2017.
- [12]Clinical and Laboratory Standards Institute. Epidemiological Cutoff Values for Antifungal Susceptibility Testing—Second Edition: M59 CLSI, Wayne, PA, USA, 2018.
Cited by
Sorted by citations
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021) · Drugs · doi:10.1007/s40265-021-01611-0 · Cited by 467 · see citing works
(BIOHAZ), E. P. O. B. H., Koutsoumanis, K., Allende, A., Alvarez‐Ordóñez, A., Bolton, D., Bover‐Cid, S., Chemaly, M., Davies, R., De Cesare, A., Hilbert, F., et al. (2020) · EFSA Journal · doi:10.2903/j.efsa.2020.6174 · Cited by 169 · see citing works
Antifungal Resistance in Candida auris: Molecular Determinants
Frías-De-León, M. G., Hernández-Castro, R., Vite-Garín, T., Arenas, R., Bonifaz, A., Castañón-Olivares, L., Acosta-Altamirano, G., & Martínez-Herrera, E. (2020) · Antibiotics · doi:10.3390/antibiotics9090568 · Cited by 93 · see citing works
Rezafungin: a novel antifungal for the treatment of invasive candidiasis
Ham, Y. Y., Lewis, J. S., & Thompson, G. R. (2021) · Future Microbiology · doi:10.2217/fmb-2020-0217 · Cited by 66 · see citing works
Investigational Agents for the Treatment of Resistant Yeasts and Molds
Seiler, G. T., & Ostrosky-Zeichner, L. (2021) · Current Fungal Infection Reports · doi:10.1007/s12281-021-00419-5 · Cited by 32 · see citing works
- Authors
- Tóth, Z., Forgács, L., Locke, J. B., Kardos, G., Nagy, F., Kovács, R., Szekely, A., Borman, A. M., & Majoros, L.
- Affiliations
- University of Debrecen (HU)
- Cidara Therapeutics (United States) (US)
- UK National Mycology Reference Laboratory (MRL), Public Health England South-West, Bristol, UK
- Public Health England (GB)
- Corresponding author
- Majoros, László
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-09-20
- Volume
- 74
- Issue
- 12
- Pages
- 3505-3510
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- PMC
- PMC6857195
- OpenAlex
- W2973507618
- Cited by
- 82
- References
- 16
- Citations by year
- 2026: 10 · 2025: 6 · 2024: 19 · 2023: 9 · 2022: 15 · 2021: 14 · 2020: 9
- FWCI
- 7.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Antimicrobial Chemotherapy (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion)
- Funders
- European Union
- European Social Fund
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Yeasts and Rust Fungi Studies
- Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Fungal Plant Pathogen Control
- Keywords
- rezafungin, echinocandins, Candida, Candida auris, Candida glabrata, Candida albicans, Candida tropicalis, Candida dubliniensis, Candida parapsilosis, Candida orthopsilosis, Candida guilliermondii, Candida metapsilosis, Candida kefyr, Candida lusitaniae, Candida krusei, Yarrowia lipolytica, Candida inconspicua, Candida pulcherrima
- MeSH terms
- Candida parapsilosis, Antifungal Agents, Candida, Microbial Sensitivity Tests, Saccharomyces cerevisiae, Candida tropicalis, Candida glabrata, Echinocandins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
